DOCSLIB.ORG

Design and Characterization of Chemical Probes Targeting the Chromodomains of Polycomb Repressive Complex I

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

DESIGN AND CHARACTERIZATION OF CHEMICAL PROBES TARGETING THE CHROMODOMAINS OF POLYCOMB REPRESSIVE COMPLEX I Jacob I. Stuckey A dissertation submitted to the faculty at the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Pharmaceutical Sciences (Chemical Biology & Medicinal Chemistry) program in the Eshelman School of Pharmacy. Chapel Hill 2016 Approved by: Stephen V. Frye David S. Lawrence Albert A. Bowers Marcey L. Waters Brian D. Strahl © 2016 Jacob I. Stuckey ALL RIGHTS RESERVED ii ABSTRACT Jacob I. Stuckey: Design and characterization of chemical probes targeting the chromodomains of Polycomb Repressive Complex I (Under the direction of Stephen V. Frye) Eukaryotic DNA is wound around histone proteins to form repeating units of nucleosomes that are packaged into higher order structures to form chromosomes. Nucleosomal packaging is dynamically regulated to control the expression of the genome through regulating access of transcription factors to specific genes in response to stimuli. Critical for these processes are modifications to the N-terminal tails of histones. In particular, methylation of specific histone lysine residues has a profound impact on transcription. This “mark” recruits protein complexes that contain methyl-lysine “reader” modules that bind to the mark and facilitate transcriptional silencing or activation of the underlying gene. Mutation and misregulation of proteins that “write,” “read” and “erase” these marks play a foundational role in the development and progression of nearly all cancers. Chemical tools that antagonize these writers, readers and erasers have been developed in recent years. These tools have been valuable in explicating the biology of these proteins, and in some cases, as therapeutic agents. Development of antagonists of methyl-lysine readers has lagged compared to both methyl-lysine writers and erasers. Herein we describe the design, development and characterization of antagonists of the chromodomain reader modules contained in Polycomb Repressive Complex I (PRC1). PRC1 contains one of five chromodomains; CBX2, -4, -6, -7 or -8. PRC1 complexes containing any one of these proteins play critical roles in normal, growth and development. Accordingly, misregulation of PRC1 chromodomains contributes to the initiation and development of numerous cancers. We developed a series of potent, peptidic antagonists of PRC1 chromodomains and an expanded set of chemical tools around one of these molecules, UNC3866, which has the highest affinity for the chromodomains of CBX4 and -7. We demonstrated the ability of UNC3866 to inhibit proliferation in a metastatic prostate cancer cells through the induction of a senescent-like state. Further optimization of UNC3866 led to a second- generation antagonist of PRC1 chromodomains with a dramatically improved residence time for CBX7 iii and increased cellular potency. This work has produced a valuable tool set for studying CBX biology and laid the ground work for continued efforts to evaluate and improve CBX antagonists as potential therapeutic agents. iv DEDICATION To the glory of God in Christ Jesus v ACKNOWLEDGMENTS Nine years ago, I delivered a speech to my high school graduating class in which I quoted the wisdom of a respected teacher and coach who insisted that “when we crossed that stage, life was going to punch us in the face.” I continued by imploring my classmates that the difference between success and failure would be determined by those who chose to get back up when life knocks us down. What I didn’t realize when I delivered that speech so long ago, was just how relevant it was for the journey on which I was about to embark. Nothing about my life even remotely resembles what I pictured that day. Looking back at the course of my life, I am grateful to even be alive, let alone where I am today. One of my most beloved childhood heroes, Sylvester Stallone’s Rocky Balboa, put it this way, “You, me, or nobody is gonna hit as hard as life. But it ain’t about how hard you hit. It’s about how hard you can get hit and keep moving forward; how much you can take and keep moving forward.” I cannot adequately express my gratitude to my family for the many, many times that they have stood beside me and kept me moving forward through everything that life has thrown at me. I want to thank my beautiful wife, Jennifer, who has loved, supported and pushed forward me forward thru even the worst of times. To my parents, Charles and Lari Stuckey, who have believed in me and supported me throughout my life, even thru times when I didn’t believe in myself. To my father, who constantly challenged me to think for myself and to “be my own man.” To my mother, who is perhaps the most disciplined, hard-working and strongest person I’ve met. I have learned so much from you both. I am the person I am today because of you. To my brother and his wife, Joshua and Linsey Stuckey, for their love and support thru the years. Their two beautiful daughters, Claire and Cora Stuckey, who have brought me so many much-needed smiles. Despite anyone else may say, are the two most adorable little girls in the world. To Paul, Susan and Jonathan Fleetwood, who have welcomed me into their family with open arms. To my grandparents, Charles and Wilma Stuckey, and Leon and Lola Calvin. Nothing saddens me more than to not be able to share the joy of what I have accomplished with you. You are loved and missed and your memory is source of inspiration for me on a daily basis. Last but not least, to vi my dogs Lizzie, Carbon and Harley, all of whom are a constant reminder that even on my worst days, as long as I have my family, life is still pretty good. Numerous others, in addition to my family have been instrumental in seeing me thru to where I am now. To my undergraduate adviser, Dr. Joshua Ring, whose passion and enthusiasm for organic chemistry and biochemistry was instrumental in my decision to change my major to Chemistry at the start of my final year as an undergraduate and to pursue the graduate studies in Pharmaceutical Sciences. To the faculty in the Division of Chemical Biology and Medicinal Chemistry at UNC for the immense amount of time, money and resources you invested in me in order to develop and train me as an independent scientist. To my adviser and mentor, Dr. Stephen V. Frye, who has been an absolute joy to work with. I have learned so much from you both in what you have explicitly taught me and from the example you have set as a person, leader and scientist (in that order). To Dr. Lindsey James, who has been tremendous friend and teacher throughout my graduate studies. You are a truly rare person who is both a great scientist and a great person. I owe a great deal of my success as a graduate student to you and know that you will continue to be an outstanding mentor to many graduate students to come. Maybe most of all, thank you for seeming to be genuinely interested when I felt the need to brag about my nieces and show off pictures of just how cute they are. To my lab mates in the Center, for their guidance, patience and hard work throughout the years. Kim Barnash, who, I’m certain, made it her sole purpose on more than a few days, to keep me humble. It has been a genuine pleasure working with and learning from you. To Kyle Konze, for your friendship and support as we started our graduate careers together and somehow made it through. I want to thank Jarod Waybright for being a great person to bounce ideas off of and an even better person to grab lunch with and forget about science altogether for a little while. To Dr. Samantha Pattenden, Jacqueline Norris Drouin, Dr. Brandi Baughman and Stephanie Cholensky for all of your hard work, support and teaching that expanded my scientific experise far beyond what I ever expected. To Dr. Brad Dickson, whose own work was critical for my success as a graduate student and who was instrumental in my transition to an independent scientist and thinker. Finally, I want to thank my committee for their time, attention and input through the years, Dr. David Lawrence, Dr. Albert Bowers, Dr. Brian Strahl and Dr. Marcey Waters. vii TABLE OF CONTENTS LIST OF TABLES ......................................................................................................................................... x LIST OF FIGURES ..................................................................................................................................... xii LIST OF ABBREVIATIONS........................................................................................................................ xv CHAPTER I: INTRODUCTION ..................................................................................................................... 1 Chromatin regulation ........................................................................................................................ 1 Therapeutic interest in chromatin regulatory proteins ...................................................................... 4 The tractability of chemical probe discovery for readers of histone lysine methylation ................... 6 Screening for antagonists of methyl-lysine readers ......................................................................... 9 Examples of previous challenges and successes of small-molecule chemical probe discovery efforts targeting methyl-lysine readers ................................................................ 11 The CBX family of chromodomains ..............................................................................................
Recommended publications
  • The Human Y Chromosome's Azoospermia Factor B (Azfb) Region

    The Human Y Chromosome's Azoospermia Factor B (Azfb) Region

    18 ORIGINAL ARTICLE J Med Genet: first published as 10.1136/jmg.40.1.18 on 1 January 2003. Downloaded from The human Y chromosome’s azoospermia factor b (AZFb) region: sequence, structure, and deletion analysis in infertile men A Ferlin, E Moro, A Rossi, B Dallapiccola, C Foresta ............................................................................................................................. J Med Genet 2003;40:18–24 See end of article for authors’ affiliations Microdeletions of the Y chromosome long arm are the most common mutations in infertile males, where ....................... they involve one or more “azoospermia factors” (AZFa, b, and c). Understanding of the AZF structure and gene content and mapping of the deletion breakpoints in infertile men are still incomplete. We Correspondence to: Professor C Foresta, have assembled a complete 4.3 Mb map of AZFb and surrounding regions by means of 38 BAC University of Padova, clones. The proximal part of AZFb consists of large repeated sequences organised in palindromes, but Department of Medical and most of it is single copy sequence. A number of known and novel genes and gene families map in this Surgical Sciences, Clinica interval, and most of them are testis specific or have testis specific transcripts. STS mapping allowed us Medica 3, Via Ospedale to identify four severely infertile subjects with a deletion in AZFb with similar breakpoints, therefore 105, 35128 Padova, Italy; [email protected] suggesting a common deletion mechanism. This deletion includes at least five single copy genes and two duplicated genes, but does not remove the historical AZFb candidate gene RBMY1. These data Revised version received suggest that other genes in AZFb may have important roles in spermatogenesis.
  • Gene Expression Effects of Lithium and Valproic Acid in a Serotonergic Cell Line

    Gene Expression Effects of Lithium and Valproic Acid in a Serotonergic Cell Line

    bioRxiv preprint doi: https://doi.org/10.1101/227652; this version posted December 1, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Gene expression effects of lithium and valproic acid in a serotonergic cell line. Diana Balasubramanian1, John F. Pearson2, Martin A. Kennedy1 1Gene Structure and Function Laboratory and Carney Centre for Pharmacogenomics, Department of Pathology, University of Otago, Christchurch, New Zealand2 2Biostatistics and Computational Biology unit, University of Otago, Christchurch. Correspondence to: Prof. M. A. Kennedy Department of Pathology University of Otago, Christchurch Christchurch, New Zealand Email: [email protected] Keywords: RNA-Seq, valproic acid, gene expression, mood stabilizer, pharmacogenomics bioRxiv preprint doi: https://doi.org/10.1101/227652; this version posted December 1, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract Valproic acid (VPA) and lithium are widely used in the treatment of bipolar disorder. However, the underlying mechanism of action of these drugs is not clearly understood. We used RNA-Seq analysis to examine the global profile of gene expression in a rat serotonergic cell line (RN46A) after exposure to these two mood stabilizer drugs. Numerous genes were differentially regulated in response to VPA (log2 fold change ≥ 1.0; i.e.
  • The Role of Y Chromosome Deletions in Male Infertility

    The Role of Y Chromosome Deletions in Male Infertility

    European Journal of Endocrinology (2000) 142 418–430 ISSN 0804-4643 INVITED REVIEW The role of Y chromosome deletions in male infertility Kun Ma, Con Mallidis and Shalender Bhasin Division of Endocrinology, Metabolism and Molecular Medicine, Department of Internal Medicine, Charles R Drew University of Medicine and Science, 1731 East 120th Street, Los Angeles, California 90050, USA (Correspondence should be addressed to K Ma; Email: [email protected]) Abstract Male infertility affects approximately 2–7% of couples around the world. Over one in ten men who seek help at infertility clinics are diagnosed as severely oligospermic or azoospermic. Recent extensive molecular studies have revealed that deletions in the azoospermia factor region of the long arm of the Y chromosome are associated with severe spermatogenic impairment (absent or severely reduced germ cell development). Genetic research into male infertility, in the last 7 years, has resulted in the isolation of a great number of genes or gene families on the Y chromosome, some of which are believed to influence spermatogenesis. European Journal of Endocrinology 142 418–430 Introduction of Infertility, with the objective of creating a standard protocol for the investigation of infertile couples. Normal Defective spermatogenesis is the result of a multitude of semen was classified as containing a sperm concentra- causes, such as diseases, malnutrition, endocrinological 6 tion of at least 20 × 10 /ml, of which more than 40% disorders, genetic defects or environmental hazards (1). are progressively motile, more than 60% are alive, and Genetic defects, such as mutations and chromosomal over 50% show normal morphology. In addition, the abnormalities, have been estimated to account for at 6 semen should contain no more than 1 × 10 /ml of white least 30% of male infertility (2).
  • Partial Azfc Deletions and Duplications: Clinical Correlates in the Italian Population

    Partial Azfc Deletions and Duplications: Clinical Correlates in the Italian Population

    FLORE Repository istituzionale dell'Università degli Studi di Firenze Partial AZFc deletions and duplications: clinical correlates in the Italian population. Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione: Original Citation: Partial AZFc deletions and duplications: clinical correlates in the Italian population / Giachini C; Laface I; Guarducci E; Balercia G; Forti G; Krausz C.. - In: HUMAN GENETICS. - ISSN 0340-6717. - STAMPA. - 124(2008), pp. 399-410. Availability: This version is available at: 2158/333113 since: 2019-11-07T18:24:55Z Terms of use: Open Access La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf) Publisher copyright claim: (Article begins on next page) 28 September 2021 Hum Genet (2008) 124:399–410 DOI 10.1007/s00439-008-0561-1 ORIGINAL INVESTIGATION Partial AZFc deletions and duplications: clinical correlates in the Italian population Claudia Giachini · Ilaria Laface · Elena Guarducci · Giancarlo Balercia · Gianni Forti · Csilla Krausz Received: 7 August 2008 / Accepted: 9 September 2008 / Published online: 21 September 2008 © Springer-Verlag 2008 Abstract The role of partial AZFc deletions of the Y potential methodological and selection biases were care- chromosome in spermatogenic impairment is currently fully avoided to detect the clinical signiWcance of partial debated. Recently, it was also reported that duplications of AZFc deletions and duplications. Our study provides strong the same region are associated with oligozoospermia in evidence that gr/gr deletion is a risk factor for impaired Han-Chinese men.
  • Nº Ref Uniprot Proteína Péptidos Identificados Por MS/MS 1 P01024

    Nº Ref Uniprot Proteína Péptidos Identificados Por MS/MS 1 P01024

    Document downloaded from http://www.elsevier.es, day 26/09/2021. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited. Nº Ref Uniprot Proteína Péptidos identificados 1 P01024 CO3_HUMAN Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 por 162MS/MS 2 P02751 FINC_HUMAN Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=4 131 3 P01023 A2MG_HUMAN Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 128 4 P0C0L4 CO4A_HUMAN Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=1 95 5 P04275 VWF_HUMAN von Willebrand factor OS=Homo sapiens GN=VWF PE=1 SV=4 81 6 P02675 FIBB_HUMAN Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2 78 7 P01031 CO5_HUMAN Complement C5 OS=Homo sapiens GN=C5 PE=1 SV=4 66 8 P02768 ALBU_HUMAN Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 66 9 P00450 CERU_HUMAN Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 64 10 P02671 FIBA_HUMAN Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 58 11 P08603 CFAH_HUMAN Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 56 12 P02787 TRFE_HUMAN Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 54 13 P00747 PLMN_HUMAN Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2 48 14 P02679 FIBG_HUMAN Fibrinogen gamma chain OS=Homo sapiens GN=FGG PE=1 SV=3 47 15 P01871 IGHM_HUMAN Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 41 16 P04003 C4BPA_HUMAN C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA PE=1 SV=2 37 17 Q9Y6R7 FCGBP_HUMAN IgGFc-binding protein OS=Homo sapiens GN=FCGBP PE=1 SV=3 30 18 O43866 CD5L_HUMAN CD5 antigen-like OS=Homo
  • Aprioritized Panel of Candidate Genes

    Aprioritized Panel of Candidate Genes

    In: Advances in Genetics Research. Volume 9 ISBN: 978-1- 62081-466-6 Editor: Kevin V. Urbano © 2012 Nova Science Publishers, Inc No part of this digital document may be reproduced, stored in a retrieval system or transmitted commercially in any form or by any means. The publisher has taken reasonable care in the preparation of this digital document, but makes no expressed or implied warranty of any kind and assumes no responsibility for any errors or omissions. No liability is assumed for incidental or consequential damages in connection with or arising out of information contained herein. This digital document is sold with the clear understanding that the publisher is not engaged in rendering legal, medical or any other professional services. Chapter 1 A PRIORITIZED PANEL OF CANDIDATE GENES TO BE EXPLORED FOR ASSOCIATIONS WITH THE BLOOD PRESSURE RESPONSE TO EXERCISE Garrett I. Ash,1,Amanda L. Augeri,2John D. Eicher,3 Michael L. Bruneau, Jr.1 and Linda S. Pescatello1 1University of Connecticut, Storrs, CT, US 2Hartford Hospital, Hartford, CT, US 3Yale University School of Medicine, New Haven, CT, US ABSTRACT Introduction. Identifying genetic variants associated with the blood pressure (BP) response to exercise is hindered by the lack of standard criteria for candidate gene selection, underpowered samples, and a limited number of conclusive whole genome studies. We developed a prioritized panel of candidate genetic variants that may increase the likelihood of finding genotype associations with the BP response to exercise when used alone or in conjunction with high throughput genotyping studies. Methods. We searched for candidate genetic variants meeting preestablished criteria using PubMed and published systematic reviews.
  • A Transcriptome-Wide Antitermination Mechanism Sustaining Identity of Embryonic Stem Cells

    A Transcriptome-Wide Antitermination Mechanism Sustaining Identity of Embryonic Stem Cells

    King’s Research Portal DOI: 10.1038/s41467-019-14204-z Document Version Peer reviewed version Link to publication record in King's Research Portal Citation for published version (APA): Kainov, Y., & Makeyev, E. (2020). A transcriptome-wide antitermination mechanism sustaining identity of embryonic stem cells. Nature Communications, 11(1), [361]. https://doi.org/10.1038/s41467-019-14204-z Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
  • Unique Signatures of Natural Background Radiation on Human Y Chromosomes from Kerala, India

    Unique Signatures of Natural Background Radiation on Human Y Chromosomes from Kerala, India

    Unique Signatures of Natural Background Radiation on Human Y Chromosomes from Kerala, India Sanjay Premi, Jyoti Srivastava, Sebastian Padinjarel Chandy, Sher Ali* Molecular Genetics Laboratory, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, India Abstract Background: The most frequently observed major consequences of ionizing radiation are chromosomal lesions and cancers, although the entire genome may be affected. Owing to its haploid status and absence of recombination, the human Y chromosome is an ideal candidate to be assessed for possible genetic alterations induced by ionizing radiation. We studied the human Y chromosome in 390 males from the South Indian state of Kerala, where the level of natural background radiation (NBR) is ten-fold higher than the worldwide average, and that from 790 unexposed males as control. Results: We observed random microdeletions in the Azoospermia factor (AZF) a, b and c regions in .90%, and tandem duplication and copy number polymorphism (CNP) of 11 different Y-linked genes in about 80% of males exposed to NBR. The autosomal homologues of Y-linked CDY genes largely remained unaffected. Multiple polymorphic copies of the Y-linked genes showing single Y-specific signals suggested their tandem duplication. Some exposed males showed unilocus duplication of DAZ genes resulting in six copies. Notably, in the AZFa region, approximately 25% of exposed males showed deletion of the DBY gene, whereas flanking genes USP9Y and UTY remained unaffected. All these alterations were detected in blood samples but not in the germline (sperm) samples. Conclusions: Exposure to high levels of NBR correlated with several interstitial polymorphisms of the human Y chromosome.
  • Male Infertility G.R

    Male Infertility G.R

    Guidelines on Male Infertility G.R. Dohle, A. Jungwirth, G. Colpi, A. Giwercman, T. Diemer, T.B. Hargreave © European Association of Urology 2008 TABLE OF CONTENTS PAGE 1. INTRODUCTION 6 1.1 Definition 1.2 Epidemiology and aetiology 6 1.3 Prognostic factors 6 1.4 Recommendations 7 1.5 References 7 2. INVESTIGATIONS 7 2.1 Semen analysis 7 2.1.1 Frequency of semen analysis 7 2.2 Recommendations 8 2.3 References 8 3. PRIMARY SPERMATOGENIC FAILURE 8 3.1 Definition 8 3.2 Aetiology 8 3.3 History and physical examination 8 3.4 Investigations 9 3.4.1 Semen analysis 9 3.4.2 Hormonal determinations 9 3.4.3 Testicular biopsy 9 3.5 Treatment 9 3.6 Conclusions 10 3.7 Recommendations 10 3.8 References 10 4. GENETIC DISORDERS IN INFERTILITY 14 4.1 Introduction 14 4.2 Chromosomal abnormalities 14 4.2.1 Sperm chromosomal abnormalities 14 4.2.2 Sex chromosome abnormalities (Klinefelter’s syndrome and variants [mosaicism] 14 4.2.3 Autosomal abnormalities 14 4.2.4 Translocations 15 4.3 Genetic defects 15 4.3.1 X-linked genetic disorders and male fertility 15 4.3.2 Kallmann’s syndrome 15 4.3.3 Androgen insensitivity: Reifenstein’s syndrome 15 4.3.4 Other X-disorders 15 4.3.5 X-linked disorders not associated with male infertility 15 4.4. Y genes and male infertility 15 4.4.1 Introduction 15 4.4.2 Clinical implications of Y microdeletions 16 4.4.2.1 Testing for Y microdeletions 16 4.4.2.2 Recommendations 16 4.4.3 Autosomal defects with severe phenotypic abnormalities as well as infertility 16 4.5 Cystic fibrosis mutations and male infertility 17 4.6 Unilateral or bilateral absence/abnormality of the vas and renal anomalies 17 4.7 Other single gene disorders 18 4.8 Unknown genetic disorders 18 4.9 Genetic and DNA abnormalities in sperm 18 4.10 Genetic counselling and ICSI 18 4.11 Conclusions 19 4.12 Recommendations 19 4.13 References 19 2 UPDATE MARCH 2007 5.
  • 2Fbm Lichtarge Lab 2006

    2Fbm Lichtarge Lab 2006

    Pages 1–8 2fbm Evolutionary trace report by report maker September 19, 2008 4.3.1 Alistat 7 4.3.2 CE 7 4.3.3 DSSP 7 4.3.4 HSSP 7 4.3.5 LaTex 7 4.3.6 Muscle 7 4.3.7 Pymol 7 4.4 Note about ET Viewer 7 4.5 Citing this work 7 4.6 About report maker 8 4.7 Attachments 8 1 INTRODUCTION From the original Protein Data Bank entry (PDB id 2fbm): Title: Acetyltransferase domain of cdy1 Compound: Mol id: 1; molecule: y chromosome chromodomain protein 1, telomeric isoform b; chain: a, b, c; engineered: yes Organism, scientific name: Homo Sapiens; 2fbm contains a single unique chain 2fbmA (251 residues long) and its homologues 2fbmC and 2fbmB. CONTENTS 2 CHAIN 2FBMA 1 Introduction 1 2.1 Q9Y6F8 overview 2 Chain 2fbmA 1 From SwissProt, id Q9Y6F8, 100% identical to 2fbmA: Description: 2.1 Q9Y6F8 overview 1 Testis-specific chromodomain protein Y 1. Organism, scientific name: 2.2 Multiple sequence alignment for 2fbmA 1 Homo sapiens (Human). Taxonomy: 2.3 Residue ranking in 2fbmA 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; 2.4 Top ranking residues in 2fbmA and their position on Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; the structure 2 Catarrhini; Hominidae; Homo. Subcellular location: 2.4.1 Clustering of residues at 25% coverage. 2 Nuclear (By similarity). Alternative products: 2.4.2 Overlap with known functional surfaces at 25% coverage. 2 Event=Alternative splicing; Named isoforms=2; Name=1; 2.4.3 Possible novel functional surfaces at 25% IsoId=Q9Y6F8-1; Sequence=Displayed; Name=2; IsoId=Q9Y6F8- coverage.
  • Exploring the Effects of Genetic Variation on Gene Regulation in Cancer in the Context of 3D Genome Structure

    Exploring the Effects of Genetic Variation on Gene Regulation in Cancer in the Context of 3D Genome Structure

    bioRxiv preprint doi: https://doi.org/10.1101/2020.10.06.328567; this version posted November 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Exploring the effects of genetic variation on gene regulation in cancer in the context of 3D genome structure by Noha Osman 1,2 and Michal Brylinski 1,3,* 1 Department of Biological Sciences, Louisiana State University, Baton Rouge, LA 70803, USA 2 Department of Cell Biology, National Research Centre, 12622 Giza, Egypt 3 Center for Computation and Technology, Louisiana State University, Baton Rouge, LA 70803, USA * Corresponding author: [email protected] Phone: (225) 578-2791 Fax: (225) 578-2597 Keywords: 3D genome structure, genetic variation, single-nucleotide polymorphism, gene regulation, chromosome conformation capture, genome-wide association study, topologically associating domains, transcription factors, enhancers, breast cancer, prostate cancer 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.10.06.328567; this version posted November 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract Numerous genome-wide association studies (GWAS) conducted to date revealed genetic variants associated with various diseases, including breast and prostate cancers. Despite the availability of these large-scale data, relatively few variants have been functionally characterized, mainly because the majority of single-nucleotide polymorphisms (SNPs) map to the non-coding regions of the human genome.
  • Obstructive Azoospermia

    Obstructive Azoospermia

    Int J Reprod BioMed Vol. 14. No. 6. pp: 383-388, June 2016 Original article Expression level of chromodomain Y (CDY): potential marker for prediction of sperm recovery in non- obstructive azoospermia Neda Heydarian1, 2 M.Sc., Raha Favaedi2 M.Sc., Mohammad Ali Sadighi Gilani3, 4 M.D., Maryam Shahhoseini2 Ph.D. 1. Department of Biology, Faculty Abstract of Science, Science and Research Branch, Islamic Azad Background: The availability of testis specific genes will be of help in choosing the University, Tehran, Iran. most promising biomarkers for the detection of testicular sperm retrieval in patients 2. Department of Genetics, with non-obstructive azoospermia (NOA). Testis specific chromodomain protein Y Reproductive Biomedicine 1 CDY1) is a histone acetyltransferase which concentrates in the round spermatid Research Center, Royan Institute ( for Reproductive Biomedicine, nucleus, where histone hyperacetylation occurs and causes the replacement of ACECR, Tehran, Iran. histones by the sperm-specific DNA packaging proteins, TNPs and PRMs. 3. Department of Andrology, Objective: The aim was to evaluate CDY1 gene as a marker for predicting of Reproductive Biomedicine successful sperm retrieval in NOA patients. Research Center, Royan Institute for Reproductive Biomedicine, Materials and Methods: This research was conducted on 29 patients with NOA ACECR, Tehran, Iran. who had undergone testicular sperm extraction (TESE) procedure. NOA patients 4. Department of Urology, Shariati were subdivided into patients with successful sperm retrieval (NOA+, n=12) and Hospital, Tehran University of patients with unsuccessful sperm retrieval (NOA-, n=17). Relative expression of Medical Sciences, Tehran, Iran. CDY1 gene and chromatin incorporation of CDY1 protein were measured by quantitative real-time polymerase chain reaction (qRT-PCR) and ELISA assay, respectively.